Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Proximal spinal muscular atrophy (SMA) is a common neuromuscular disorder causing infant death in half of all patients. Homozygous absence of the survival motor neuron gene (SMN1) is the primary cause of SMA, while SMA severity is mainly determined by the number of SMN2 copies. One SMN2 copy produces only about 10% of full-length protein identical to SMN1, whereas the majority of SMN2 transcripts is aberrantly spliced due to a silent mutation within an exonic splicing enhancer in exon 7. However, correct splicing can be restored by over-expression of the SR-like splicing factor Htra2-beta 1. We show that in fibroblast cultures derived from SMA patients treated with therapeutic doses (0.5-500 microM) of valproic acid (VPA), the level of full-length SMN2 mRNA/protein increased 2- to 4-fold. Importantly, this up-regulation of SMN could be most likely attributed to increased levels of Htra2-beta 1 which facilitates the correct splicing of SMN2 RNA as well as to an SMN gene transcription activation. Especially at low VPA concentrations, the restored SMN level depended on the number of SMN2 copies. Moreover, VPA was able to increase SMN protein levels through transcription activation in organotypic hippocampal brain slices from rats. Finally, VPA also increased the expression of further SR proteins, which may have important implications for other disorders affected by alternative splicing. Since VPA is a drug highly successfully used in long-term epilepsy therapy, our findings open the exciting perspective for a first causal therapy of an inherited disease by elevating the SMN2 transcription level and restoring its correct splicing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
A simple method for organotypic cultures of nervous tissue
Stoppini, L., Buchs, P.-A., & Muller, D. (1991) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(91)90128-m · Cited by 3,089
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,532
Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002) · The American Journal of Human Genetics · doi:10.1086/338627 · Cited by 1,004
Hockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P. A. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437870100 · Cited by 845
What's Up and Down with Histone Deacetylation and Transcription?
Pazin, M. J., & Kadonaga, J. T. (1997) · Cell · doi:10.1016/s0092-8674(00)80211-1 · Cited by 821
Cartegni, L., & Krainer, A. R. (2002) · Nature Genetics · doi:10.1038/ng854 · Cited by 730
Wirth, B. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200003)15:3<228::aid-humu3>3.0.co;2-9 · Cited by 667
International SMA Consortium Meeting (26–28 June 1992, Bonn, Germany)
Munsat, T. L., & Davies, K. E. (1992) · Neuromuscular Disorders · doi:10.1016/s0960-8966(06)80015-5 · Cited by 666
Cited by
Items 201–300 of 388
Potential non-oncological applications of histone deacetylase inhibitors.
Ververis, K., & Karagiannis, T. C. (2011) · Europe PMC (PubMed Central) · Cited by 32
Liu, H., Yazdani, A., Murray, L. M., Beauvais, A., & Kothary, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101225 · Cited by 29
Development of Histone Deacetylase Inhibitors as Therapeutics for Neurological Disease
Gottesfeld, J. M., & Pandolfo, M. (2009) · Future Neurology · doi:10.2217/fnl.09.55 · Cited by 32
Paciolla, C., Manganelli, M., Chiano, M. D., Montenegro, F., Gallone, A., Sallustio, F., & Guida, G. (2025) · Cells · doi:10.3390/cells14221823 · Cited by 42
Drug treatment for spinal muscular atrophy type I
Wadman, R. I., van der Pol, W. L., Bosboom, W. M., Asselman, F., van den Berg, L. H., Iannaccone, S. T., & Vrancken, A. F. J. E. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006281.pub5 · Cited by 32
Emerging treatment options for spinal muscular atrophy
Burnett, B. G., Crawford, T. O., & Sumner, C. J. (2009) · Current Treatment Options in Neurology · doi:10.1007/s11940-009-0012-x · Cited by 27
Valproic acid blocks excitability in SMA type I mouse motor neurons
Rak, K., Lechner, B. D., Schneider, C. B., Drexl, H., Sendtner, M., & Jablonka, S. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.08.014 · Cited by 32
SR Proteins as Potential Targets for Therapy
Soret, J., Gabut, M., & Tazi, J. (2006) · Progress in molecular and subcellular biology · doi:10.1007/978-3-540-34449-0_4 · Cited by 32
Spinal muscular atrophy: Advances in research and consensus on care of patients
Wang, C. H., & Lunn, M. R. (2008) · Current Treatment Options in Neurology · doi:10.1007/s11940-008-0044-7 · Cited by 27
Rouget, R., Vigneault, F., CODIO, C., Rochette, C., Paradis, I., Drouin, R., & Simard, L. R. (2005) · Biochemical Journal · doi:10.1042/bj20041024 · Cited by 34
Splicing therapeutics in SMN2 and APOB.
Khoo, B. C. E., & Krainer, A. R. (2009) · PubMed · Cited by 32
Ando, S., Funato, M., Ohuchi, K., Kameyama, T., Inagaki, S., Seki, J., Kawase, C., Tsuruma, K., Shimazawa, M., Kaneko, H., et al. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.08.005 · Cited by 28
Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges
Haque, U. S., & Yokota, T. (2024) · Genes · doi:10.3390/genes15080999 · Cited by 23
Hydroxyurea enhances SMN2 gene expression through nitric oxide release
Cheng, X., Chen, X., Grzeschik, S. M., Ganta, M., & Wang, C. H. (2010) · Neurogenetics · doi:10.1007/s10048-010-0268-z · Cited by 25
Therapeutic developments in spinal muscular atrophy
Sproule, D. M., & Kaufmann, P. (2010) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285610369026 · Cited by 26
Sangiuolo, F. C., Filareto, A., Spitalieri, P., Scaldaferri, M. L., Mango, R., Bruscia, E. M., Citro, G., Brunetti, E., Felici, M. D., & Novelli, G. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.869 · Cited by 25
Histone deacetylase (HDACs) inhibitors: Clinical applications
Shanmukha, K. D., Paluvai, H., Lomada, S. K., Gokara, M., & Kalangi, S. K. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.02.011 · Cited by 29
Solving the puzzle of spinal muscular atrophy: What are the missing pieces?
Tiziano, F. D., Melki, J., & Simard, L. R. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36251 · Cited by 26
Hensel, N., Cieri, F., Santonicola, P., Tapken, I., Schüning, T., Taiana, M. M., Pagliari, E., Joseph, A., Fischer, S., Heidrich, N., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2007785118 · Cited by 23
Therapeutic Strategies For The Treatment Of Spinal Muscular Atrophy
Cherry, J. J., & Androphy, E. J. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.107 · Cited by 26
Capturing Alzheimer's disease genomes with induced pluripotent stem cells: prospects and challenges
Israel, M. A., & Goldstein, L. S. B. (2011) · Genome Medicine · doi:10.1186/gm265 · Cited by 24
Pros, E., Larriba, S., López, E., Ravella, A., Gili, M., Kruyer, H., Valls, J., Serra, E., & Lázaro, C. (2006) · Human Mutation · doi:10.1002/humu.20396 · Cited by 22
Valproate reduces collagen and osteonectin in cultured bone cells
Humphrey, E., Morris, G. E., & Fuller, H. R. (2013) · Epilepsy Research · doi:10.1016/j.eplepsyres.2013.06.011 · Cited by 22
Therapy Development for Spinal Muscular Atrophy in SMN Independent Targets
Tsai, L. (2012) · Neural Plasticity · doi:10.1155/2012/456478 · Cited by 22
A Cell System for Phenotypic Screening of Modifiers of SMN2 Gene Expression and Function
Li, D. K., Tisdale, S., Espinoza‐Derout, J., Saieva, L., Lotti, F., & Pellizzoni, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071965 · Cited by 23
Pluripotent Human Stem Cells: A Novel Tool in Drug Discovery
Phillips, B. W., & Crook, J. M. (2010) · BioDrugs · doi:10.2165/11532270-000000000-00000 · Cited by 25
Kaneko, K., Arakawa, R., Urano, M., Aoki, R., & Saito, K. (2017) · Brain and Development · doi:10.1016/j.braindev.2017.04.018 · Cited by 22
Transcriptional and Splicing Regulation of Spinal Muscular Atrophy Genes
Singh, N. N., Howell, M. D., & Singh, R. N. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00005-7 · Cited by 24
Spinal Muscular Atrophy Disease Modifiers
Wirth, B., Mendoza-Ferreira, N., & Torres‐Benito, L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00012-4 · Cited by 24
Chong, L. C., Gandhi, G., Lee, J. M., Yeo, W. W. Y., & Choi, S. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168962 · Cited by 26
Spinal muscular atrophy disease: a literature review for therapeutic strategies.
Stavarachi, M., Apostol, P., Toma, M., Cimponeriu, D., & Gavrilă, L. (2010) · PubMed Central · Cited by 21
Tsirikos, A. I., & Baker, A. D. L. (2006) · Current Orthopaedics · doi:10.1016/j.cuor.2006.09.006 · Cited by 21
Aznarez, I., Zielenski, J., Rommens, J. M., Blencowe, B. J., & Tsui, L. ‐. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2006.045880 · Cited by 21
Elshafay, A., Hieu, T. H., Doheim, M. F., Kassem, M. A. M., ELdoadoa, M. F., Holloway, S. K., Abo-elghar, H., Hirayama, K., & Huy, N. T. (2019) · CNS Drugs · doi:10.1007/s40263-019-00606-6 · Cited by 20
Farrelly-Rosch, A., Lau, C. L., Patil, N. A., Turner, B. J., & Shabanpoor, F. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.02.016 · Cited by 22
Modulation of aberrant NF1 pre-mRNA splicing by kinetin treatment
Pros, E., Fernández‐Rodríguez, J., Benito‐Aracil, L., Ravella, A., Capellá, G., Blanco, I., Serra, E., & Lázaro, C. (2009) · European Journal of Human Genetics · doi:10.1038/ejhg.2009.212 · Cited by 18
Spinal muscular atrophy: Factors that modulate motor neurone vulnerability
Tu, W.-Y., Simpson, J. E., Highley, J. R., & Heath, P. R. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.01.011 · Cited by 21
Renusch, S. R., Harshman, S. W., Pi, H., Workman, E., Wehr, A. M., Li, X., Prior, T. W., Elsheikh, B., Swoboda, K. J., Simard, L. R., et al. (2015) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-150081 · Cited by 18
Applicability of Histone Deacetylase Inhibition for the Treatment of Spinal Muscular Atrophy
Lunke, S., & El‐Osta, A. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0209-2 · Cited by 20
Somers, E., Rießland, M., Schreml, J., Wirth, B., Gillingwater, T. H., & Parson, S. H. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.03.052 · Cited by 18
Current advances in drug development in spinal muscular atrophy
Singh, P., Liew, W. K. M., & Darras, B. T. (2013) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32836565ac · Cited by 17
Chemical Genetics and Orphan Genetic Diseases
Lunn, M. R., & Stockwell, B. R. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.09.005 · Cited by 19
Perspectives on models of spinal muscular atrophy for drug discovery
Butchbach, M. E. R., & Burghes, A. H. M. (2004) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2004.07.001 · Cited by 17
Drug treatment for spinal muscular atrophy types II and III
Bosboom, W. M., Vrancken, A. F. J. E., van den Berg, L. H., Wokke, J. H. J., & Iannaccone, S. T. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006282.pub2 · Cited by 25
Butyrate prevents muscle atrophy after sciatic nerve crush
Walsh, M. E., Bhattacharya, A., Liu, Y., & Remmen, H. V. (2015) · Muscle & Nerve · doi:10.1002/mus.24622 · Cited by 19
An SMA Project Report: Neural Cell-Based Assays Derived from Human Embryonic Stem Cells
Wilson, P. G., Cherry, J. J., Schwamberger, S., Adams, A. M., Zhou, J., Shin, S., & Stice, S. L. (2007) · Stem Cells and Development · doi:10.1089/scd.2007.0061 · Cited by 18
Biomarkers in Rare Disorders: The Experience with Spinal Muscular Atrophy
Tiziano, F. D., Neri, G., & Brahe, C. (2010) · International Journal of Molecular Sciences · doi:10.3390/ijms12010024 · Cited by 16
Damante, G. (2010) · Oncology Reports · doi:10.3892/or.2010.1075 · Cited by 22
PIOTROWSKA, H., & Jagodziński, P. P. (2007) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2007.03.007 · Cited by 17
Ciura, J., & Jagodziński, P. P. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0026-1 · Cited by 20
Erden, D. D., Bora, G., Dalkara, S., DEMİR, A. S., & Erdem‐Yurter, H. (2011) · Archives of Medical Science · doi:10.5114/aoms.2011.22072 · Cited by 15
Drosophila SMN2 minigene reporter model identifies moxifloxacin as a candidate therapy for SMA
Konieczny, P., & Artero, R. D. (2019) · The FASEB Journal · doi:10.1096/fj.201802554rrr · Cited by 15
Hölsken, A., Eyüpoglu, I. Y., Lueders, M., Tränkle, C., Dieckmann, D., Buslei, R., Hahnen, E., Blümcke, I., & Siebzehnrübl, F. A. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0082-8 · Cited by 17
Developing therapies for spinal muscular atrophy
Wertz, M. H., & Şahin, M. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12813 · Cited by 17
Functional analysis and in vitro correction of splicing FAH mutations causing tyrosinemia type I
Pérez-Carro, R., Sánchez-Alcudia, R., Pérez, B., Navarrete, R., Pérez‐Cerdá, C., Ugarte, M., & Desviat, L. R. (2013) · Clinical Genetics · doi:10.1111/cge.12243 · Cited by 14
Chiriboga, C. A. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00529-8 · Cited by 14
Pruss, R. M., Giraudon‐Paoli, M., Morozova, S., Berna, P. P., Abitbol, J., & Bordet, T. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.228 · Cited by 15
Mohseni, J. H., Al-Najjar, B. O., Wahab, H. A., Zabidi-Hussin, Z. A. M. H., & Sasongko, T. H. (2016) · Journal of Human Genetics · doi:10.1038/jhg.2016.61 · Cited by 14
The CFTR Gene: Structure, Mutations and Specific Therapeutic Approaches
Nissim‐Rafinia, M., Linde, L., & Kerem, B. (2005) · KARGER eBooks · doi:10.1159/000088467 · Cited by 14
Mattis, V. B., Butchbach, M. E. R., & Lorson, C. L. (2008) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2008.07.024 · Cited by 13
HnRNP C1/C2 may regulate exon 7 splicing in the spinal muscular atrophy gene SMN1.
Irimura, S. C., Kitamura, K., Kato, N., Saiki, K., Takeuchi, A., Gunadi, G., Matsuo, M., Nishio, H., & Lee, M. J. (2009) · PubMed · doi:10.24546/81000983 · Cited by 13
Hinzpeter, A., Aissat, A., de Becdelièvre, A., Bieth, É., Sondo, E., Martin, N., Costes, B., Costa, C., Goossens, M., Galietta, L. J. V., et al. (2012) · Human Mutation · doi:10.1002/humu.22236 · Cited by 13
The protective effects of beta-lactam antibiotics in motor neuron disorders
Hedlund, E. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.06.002 · Cited by 13
Vitte, J., Attali, R., Warwar, N., Gurt, I., & Melki, J. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-2813-6_16 · Cited by 12
Loading Controls for Western Blots
Johnson, M. (2012) · Materials and Methods · doi:10.13070/mm.en.2.114 · Cited by 11
Tariq, F. A., Holčík, M., & MacKenzie, A. (2013) · InTech eBooks · doi:10.5772/53800 · Cited by 21
Atrofia muscular espinal: Caracterización clínica, electrofisiológica y molecular de 26 pacientes
Claudia Castiglioni, T., Lévican, J., Rodillo, E., GARMENDIA, M. A., Díaz, A., PIZARRO, L., & Contreras, L. (2011) · Revista médica de Chile · doi:10.4067/s0034-98872011000200009 · Cited by 11
Splicing Modulation as a Modifier of the CFTR Function
Nissim‐Rafinia, M., & Kerem, B. (2006) · Progress in molecular and subcellular biology · doi:10.1007/978-3-540-34449-0_10 · Cited by 12
Drug treatment for spinal muscular atrophy types II and III
Wadman, R. I., Bosboom, W. M., van den Berg, L. H., Wokke, J. H. J., Iannaccone, S. T., & Vrancken, A. F. J. E. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006282.pub3 · Cited by 13
Dachs, E., Piedrafita, L., Hereu, M., Esquerda, J. E., & Calderó, J. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.07.026 · Cited by 10
Naturally Occurring Plant Polyphenols as Potential Therapies for Inherited Neuromuscular Diseases
Fuller, H. R., Humphrey, E., & Morris, G. E. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.165 · Cited by 10
Mazzarella, N., Giangrieco, I., Visone, S., Santonicola, P., Achenbach, J., Zampi, G., Tamburrini, M., Schiavi, E. D., & Ciardiello, M. A. (2019) · Food Science & Nutrition · doi:10.1002/fsn3.1078 · Cited by 11
Research on neurodegenerative diseases using induced pluripotent stem cells
Imamura, K., & Inoue, H. (2012) · Psychogeriatrics · doi:10.1111/j.1479-8301.2011.00394.x · Cited by 11
Advances and challenges in developing a therapy for spinal muscular atrophy
Anderton, R. S., & Mastaglia, F. L. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1059757 · Cited by 13
PIOTROWSKA, H., & Jagodziński, P. P. (2009) · Archives of Medical Research · doi:10.1016/j.arcmed.2009.02.004 · Cited by 14
Current methodological issues in the study of children with inherited neuromuscular disorders
Mercuri, E. M., Messina, S., Pane, M., & Bertini, E. (2008) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2008.02066.x · Cited by 10
A Study of valproic acid for patients with spinal muscular atrophy
Saito, T., Nurputra, D. K., Harahap, N. I. F., Harahap, I. S. K., Yamamoto, H., Muneshige, E., Nishizono, H., Matsumura, T., Fujimura, H., Sakoda, S., et al. (2014) · Neurology and Clinical Neuroscience · doi:10.1111/ncn3.140 · Cited by 10
Atrofia muscular espinhal: diagnóstico, tratamento e perspectivas futuras
Baioni, M. T. C., & Ambiel, C. R. (2010) · Jornal de Pediatria · doi:10.1590/s0021-75572010000400004 · Cited by 21
Iwatani, S., Harahap, N. I. F., Nurputra, D. K., Tairaku, S., Shono, A., Kurokawa, D., Yamana, K., Thwin, K. K. M., Yoshida, M., Mizobuchi, M., et al. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00194 · Cited by 9
Sumner, C. J., & Fischbeck, K. H. (2007) · Elsevier eBooks · doi:10.1016/b978-012088592-3/50046-3 · Cited by 9
HDAC4 Inhibitors as Antivascular Senescence Therapeutics
Huang, C., Lin, Z., Liu, X., Ding, Q., Cai, J., Zhang, Z., Rose, P., & Zhu, Y. Z. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3087916 · Cited by 11
Alternative isoform discrimination by the next generation of expression profiling microarrays
Pando, M. P., Kotraiah, V., McGowan, K. M., Bracco, L. P., & Einstein, R. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.4.613 · Cited by 9
Therapeutics development for spinal muscular atrophy
Sumner, C. J. (2006) · Neurotherapeutics · doi:10.1007/bf03207053 · Cited by 10
Mankodi, A. K., & Ashizawa, T. (2003) · Neurology · doi:10.1212/wnl.61.10.1330 · Cited by 9
Lumpkin, C. J., Harris, A. W., Connell, A. J., Kirk, R. W., Whiting, J. A., Saieva, L., Pellizzoni, L., Burghes, A. H. M., & Butchbach, M. E. R. (2023) · Scientific Reports · doi:10.1038/s41598-023-37496-0 · Cited by 9
The Relevance of Spinal Muscular Atrophy Biomarkers in the Treatment Era
Maretina, M. A., Koroleva, V., Shchugareva, L. M., Glotov, A. S., & Kiselev, A. (2024) · Biomedicines · doi:10.3390/biomedicines12112486 · Cited by 10
Viollet, L., & Melki, J. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59565-2.00010-1 · Cited by 8
Treatment strategies for spinal muscular atrophy
Fuller, H. R., Barišić, M., Šešo-Šimić, Đ., Špeljko, T., Morris, G., & Šimić, G. (2010) · Translational Neuroscience · doi:10.2478/v10134-010-0045-4 · Cited by 7
Arakawa, M., Arakawa, R., Tatsumi, S., Aoki, R., Saito, K., & Nomoto, A. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.09.087 · Cited by 9
Rescue of Isolated GH Deficiency Type II (IGHD II) via Pharmacologic Modulation of GH-1 Splicing
Miletta, M. C., Petkovic, V., Eblé, A., Flück, C. E., & Mullis, P. (2016) · Endocrinology · doi:10.1210/en.2015-2038 · Cited by 7
Development and Testing of Biomarkers in Spinal Muscular Atrophy
Arnold, W. D., Simard, L. R., Rutkove, S. B., & Kolb, S. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00024-0 · Cited by 8
Spinal Muscular Atrophy and Common Therapeutic Advances
Qomi, S. B., Asghari, A., Salmaninejad, A., & Mojarrad, M. (2019) · Fetal and Pediatric Pathology · doi:10.1080/15513815.2018.1520374 · Cited by 9
Cintado, M. Á., la Casa, L. G. D., & González, G. (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12483 · Cited by 7
Pharmacologic Correction of Dominant‐Negative GH1 Deficiency Causing Mutations
Poling, J., Phillips, J. A., III, Cogan, J. D., & Hamid, R. (2011) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2011.00290.x · Cited by 7
Lomonte, P., Baklouti, F., & Binda, O. (2020) · Biochemistry · doi:10.1021/acs.biochem.9b01124 · Cited by 5
Valproate and spinal muscular atrophy (Review)
Young, P. J., Young, E. C., Brandom, K. G., & Natasha, G. (2008) · Molecular Medicine Reports · doi:10.3892/mmr.1.2.161 · Cited by 7
Wasilewska-Dziubińska, E., Gajewska, A., Wolińska‐Witort, E., Chmielowska, M., Martyńska, L., Elbanowski, J., & Kochman, K. (2011) · PubMed · Cited by 7
Degenerative Motor, Sensory, and Autonomic Disorders
Siddique, N., Sufit, R. L., & Siddique, T. (2007) · Elsevier eBooks · doi:10.1016/b978-141603618-0.10036-0 · Cited by 8
Farrar, M. A., & Kiernan, M. C. (2011) · Wiley eBooks · doi:10.1002/9780470015902.a0006011.pub2 · Cited by 9
Zhang, X., Yin, A., Zhu, X., Ding, Q., Wang, C., & Chen, Y. (2011) · Oncology Reports · doi:10.3892/or.2011.1601 · Cited by 7
Metadata
- Authors
- Brichta, L.
- Affiliations
- University of Bonn (DE)
- Corresponding author
- Brichta, L.
- ORCID
- Brichta, L.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-08-05
- Volume
- 12
- Issue
- 19
- Pages
- 2481-2489
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2151318390
- Cited by
- 382
- References
- 41
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 7 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 6 · 2019: 12 · 2018: 8 · 2017: 11 · 2016: 14 · 2015: 15 · 2014: 15 · 2013: 31 · 2012: 18
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- valproic acid, spinal muscular atrophy, SMN2, SMN1, SR proteins, alternative splicing, exonic splicing enhancers, drug repurposing, inherited neuromuscular disease
- MeSH terms
- Animals, Antibodies, Monoclonal, Cells, Cultured, Dose-Response Relationship, Drug, Exons, Fibroblasts, Gene Expression Regulation, Hippocampus, Humans, Muscular Atrophy, Spinal, Nerve Tissue Proteins, Organ Culture Techniques, RNA Splicing, RNA, Messenger, Time Factors, Transcription, Genetic, Valproic Acid, Blotting, Western, Genetic Therapy, Rats, Wistar, Gene Deletion, GABA Agents, Reverse Transcriptase Polymerase Chain Reaction, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.